Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network

Background Knowledge of real‐world antihypertensive use is limited to prevalent hypertension, limiting our understanding of how treatment evolves and its contribution to persistently poor blood pressure control. We sought to characterize antihypertensive initiation among new users. Methods and Results Using Medicaid and Medicare data from the OneFlorida+ Clinical Research Consortium, we identified new users of ≥1 first‐line antihypertensives (angiotensin‐converting enzyme inhibitor, calcium channel blocker, angiotensin receptor blocker, thiazide diuretic, or β‐blocker) between 2013 and 2021 among adults with diagnosed hypertension, and no antihypertensive fill during the prior 12 months. We evaluated initial antihypertensive regimens by class and drug overall and across study years and examined variation in antihypertensive initiation across demographics (sex, race, and ethnicity) and comorbidity (chronic kidney disease, diabetes, and atherosclerotic cardiovascular disease). We identified 143 054 patients initiating 188 995 antihypertensives (75% monotherapy; 25% combination therapy), with mean age 59 years and 57% of whom were women. The most commonly initiated antihypertensive class overall was angiotensin‐converting enzyme inhibitors (39%) followed by β‐blockers (31%), calcium channel blockers (24%), thiazides (19%), and angiotensin receptor blockers (11%). With the exception of β‐blockers, a single drug accounted for ≥75% of use of each class. β‐blocker use decreased (35%–26%), and calcium channel blocker use increased (24%–28%) over the study period, while initiation of most other classes remained relatively stable. We also observed significant differences in antihypertensive selection across demographic and comorbidity strata. Conclusions These findings indicate that substantial variation exists in initial antihypertensive prescribing, and there remain significant gaps between current guideline recommendations and real‐world implementation in early hypertension care.

[1]  Byron C. Jaeger,et al.  Blood Pressure Control Among US Adults, 2009 to 2012 Through 2017 to 2020 , 2022, Hypertension.

[2]  A. Zaslavsky,et al.  National Trends in Antihypertensive Treatment Among Older Adults by Race and Presence of Comorbidity, 2008 to 2017 , 2022, Journal of General Internal Medicine.

[3]  J. Spence Faculty Opinions recommendation of Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  Dave L Dixon,et al.  Factors Associated with Antihypertensive Monotherapy Among US Adults with Treated Hypertension and Uncontrolled Blood Pressure Overall and by Race/Ethnicity, NHANES 2013-2018. , 2021, American heart journal.

[5]  A. Moran,et al.  Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018 , 2021, Hypertension.

[6]  G. Mancia,et al.  Adherence to treatment by initial antihypertensive mono and combination therapies. , 2021, American journal of hypertension.

[7]  D. Madigan,et al.  Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients , 2021, Hypertension.

[8]  Dandan Li,et al.  Frequency and Patterns of Prescribing Antihypertensive Agents in Outpatient Kidney Transplant Recipients Among Six Cities in China from 2011 to 2018. , 2021, Clinical therapeutics.

[9]  A. Moran,et al.  Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005–2016 , 2020, Hypertension.

[10]  George Hripcsak,et al.  Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis , 2019, The Lancet.

[11]  Sum Lam,et al.  Patterns of Antihypertensive Drug Utilization among US Adults with Diabetes and Comorbid Hypertension: The National Health and Nutrition Examination Survey 1999-2014 , 2019, Clinical Medicine Insights. Cardiology.

[12]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[13]  R. Brook,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[14]  R. Stafford,et al.  Current Trends of Hypertension Treatment in the United States , 2017, American journal of hypertension.

[15]  R. Stafford,et al.  National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012 , 2015, PloS one.

[16]  D. Tanné,et al.  Trends in antihypertensive treatment – Lessons from the National Acute Stroke Israeli (NASIS) registry , 2014, Blood pressure.

[17]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[18]  Li-sheng Liu,et al.  Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns. , 2014, American journal of hypertension.

[19]  Jay R. Desai,et al.  Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes , 2013, Diabetes Care.

[20]  H. Blix,et al.  Choice of initial antihypertensive drugs and persistence of drug use—a 4-year follow-up of 78,453 incident users , 2012, European Journal of Clinical Pharmacology.

[21]  J. Sowers,et al.  How early should blood pressure control be achieved for optimal cardiovascular outcomes? , 2011, Journal of Human Hypertension.

[22]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[23]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[24]  J. Hasford,et al.  A population-based European cohort study of persistence in newly diagnosed hypertensive patients , 2002, Journal of Human Hypertension.

[25]  E. Argulian,et al.  Age Differences in Treatment and Control of Hypertension in US Physician Offices, 2003-2010: A Serial Cross-sectional Study. , 2016, The American journal of medicine.

[26]  S. Bangalore,et al.  Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. , 2016, Mayo Clinic proceedings.

[27]  Jackson T. Wright,et al.  Evidence-Based Guideline for the Management of High Blood Pressure in Adults , 2012 .

[28]  F. Zacharias Beta blockers in hypertension. , 1973, Bruxelles medical.